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Body mass index (BMI)Abstract Background: Asthma in the obese represents a growing epidemic of pulmonary disease,
and these patients are distinct from non obese asthmatics. Accordingly, studies on the pathogenesis
of asthma in the obese are critical to guide our understanding of this disease process; such studies
will ultimately guide the development of new therapies to treat the obese asthmatic population.
Patients and methods: Eighty (80) subjects were classiﬁed according to BMI into 4 groups:
Group 1 (20 subjects): control none obese, they were apparently healthy subjects with BMI
22.9 ± 0.68 kg/m2. Group 2 (20 subjects): control obese, they were apparently healthy subjects with
BMI 36.16 ± 3.15 kg/m2. Group 3 (20 patients): they were none obese asthmatic patients with BMI
22.97 ± 1.13 kg/m2. Group 4 (20 patients): they were obese asthmatic patients with BMI
34.9 ± 2.4 kg/m2.
Results: There was a higher leptin serum level in obese control (34.81 ± 2.32 pg/ml) compared
to none obese control (9.73 ± 0.78 pg/ml) (p< 0.01). Moreover, there was a higher leptin serum
level in obese asthmatic patients (39.74 ± 3.26 pg/ml) compared to none obese asthmatic patients
(23.58 ± 1.99 pg/ml) (P< 0.01). There was a lower adiponectin serum level in obese control
(4.95 ± 1.32) than non obese control (7.74 ± 3.13) (P< 0.05) and in obese asthmatic patients
(3.3 ± 1.4) than non obese asthmatic patients (5.99 ± 1.5) (P< 0.01).
Conclusion: There is a strong association between asthma and obesity regarding serum level of
leptin and adiponectin.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
There is a worldwide epidemic of obesity. In the USA, the
prevalence of obesity, deﬁned as a body mass index (BMI)
P30 kg/m2, has increased among adults aged 20–74 years
from, 15% in the late 1970 to, 35% in 2010. The obesity epi-
demic has impacted both developed and developing nationsrculosis.
530 A. Salah et al.throughout the world. The World Health Organization esti-
mates that worldwide, 2 billion people are either obese or over-
weight [1]. Not only is obesity a risk factor for asthma, but
asthma in the obese has distinct features compared to disease
in the non-obese. Obese asthmatics tend to have more severe
disease [2,3] respond less well to standard controller therapy,
[4] and have evidence of cellular glucocorticoid resistance [5].
This despite the fact they do not appear to have worsened air-
way inﬂammation as measured by either sputum eosinophils or
neutrophils [6]. Asthma is associated with airway inﬂammation
and reversible airﬂow obstruction. Obese asthma patients have
more severe disease with increased asthma exacerbations,
decreased asthma control, and decreased steroid responsive-
ness [7].
Asthma in the obese represents a growing epidemic of pul-
monary disease, and these patients are distinct from non obese
asthmatics. Accordingly, studies on the pathogenesis of
asthma in the obese are critical to guide our understanding
of this disease process; such studies will ultimately guide the
development of new therapies to treat the obese asthmatic
population [8].Patients and methods
This study was carried out at Chest Department, Outpatient
Clinics at Zagazig university hospitals from April 2013 to
October 2013.
Study design: Prospective case control comparative study.
Type of selection: none randomized.
Subjects
The study included 80 subjects who were classiﬁed into 4
groups according to BMI and GINA 2012 [9]. Group 1 (20
subjects): control none obese, they were apparently healthy
subjects. Group 2 (20 subjects): control obese, they were
apparently healthy subjects. Group 3 (20 patients): they were
none obese asthmatic patients. Group 4 (20 patients): they
were obese asthmatic patients. All Asthmatic persons were
diagnosed according to (GINA. 2012) [9].Inclusion criteria
(1) Asthmatic patients either males or females, non-smokers or
ex-smokers for at least 3 months well controlled on inhaled
corticosteroids (ICS) with or without long acting b 2 agonist
(LABA) [9]. (2) Obese BMIP 30.3) Non obese have BMI
(24.9–20) [10].Exclusion criteria
Individuals with one or more of the following: known infec-
tious disease, cardiovascular, rheumatic, malignancy, liver
and kidney disorders, breast-feeding and pregnant women,
and individuals with obesity due to secondary factors were
excluded from the study [11]. Bronchial asthma patients who
were receiving systemic steroids in the preceding 4 weeks were
also excluded. [12].Methods
All persons were subjected to:
(1) Full medical history: Including history of asthma symp-
toms especially; breathlessness, chest tightness, wheezing and
cough, family history of asthma or atopic diseases, co-morbid
disorders eg, DM, HTN, heart failure, liver cell failure and
renal failure. (2) Full clinical examination (general examina-
tion and local chest examination): 1 – Weight which was mea-
sured in kgm, height which was measured in meters and
accordingly BMI was calculated. (3) Plain chest X-ray: (pos-
tero-anterior view and lateral view) and HRCT chest if needed.
(4) Full conventional laboratory investigation eg, CBC, ESR,
RBS, liver function tests. (5) Spirometric ventilatory function
was done by (Minispir S/N C00215): FEV1/FVC ratio
<0.75–0.8 suggests airﬂow limitation. The degree of reversibil-
ity in FEV1 which indicates a diagnosis of asthma is generally
accepted as 12% and 200 ml from the pre-bronchodilator
value 15 min after inhalation of 200 lg of salbutamol [9]. (6)
Measurement of inﬂammatory markers serum level: Fasting
venous blood samples were collected at 09.00 h. After cen-
trifuging at 4 C, the blood was stored at 70 C until ana-
lyzed [11]:
(A) Leptin: measurement of leptin serum level was done for
all cases and control group by ELISA ‘‘Enzyme – linked
immunosorbent assay technique’’. By (Bio-Rad,
Hercules, CA, USA) in accordance with the manufac-
turer’s guidelines. The minimum measurable level of lep-
tin is 7.8 pg/ml.
(B) Adiponectin: measurement of adiponectin serum level
was done for all cases and control group by ELISA
‘‘Enzyme – linked immunosorbent assay technique’’.
‘ELISA KIT’ by (anti Biotech OY, Orgenium
Laboratories Business Unit, Finland).
Statistical analysis
Statistical analysis was performed with Epi Info version 7
and the SPSS version 19 statistical software package (SPSS
Inc., Chicago, IL, USA). Data are presented as mean ± SD.
For time point differences, a two-sample t test was used. P
value <0.05 was considered signiﬁcant.Results
Demographic data of the studied population are demonstrated
in Table 1 where, group 1 includes 20 subjects (10 males and
10 females) with mean age 33.4 ± 7.6 years, group 2 includes
20 subjects (11 males and 9 females) with mean age
33.6 ± 9.6 years, group 3 includes 20 asthmatic patients (11
males and 9 females) with mean age 31.9 ± 6.2 years, group
4 includes 20 obese asthmatic patients (9 males and 11 females
with mean age 34.7 ± 8.08 with P> 0.05.
Table 2 shows the mean value of BMI in the studied pop-
ulation with highly statistical differences between group 1 with
BMI 22.9 ± 0.68 kg/m2, and group 2 with BMI
36.16 ± 3.15 kg/m2, and between group 3 with BMI
Table 1 Demographic data of the studied population.
Group 1 Group 2 Group 3 Group 4 P value
Non obese control Obese control Non obese asthmatics Obese asthmatics
Age (mean ± SD) 33.4 ± 7.6 33.6 ± 9.6 31.9 ± 6.2 34.7 ± 8.08 t-Test >0.05
Sex Chi-square >0.05
Male N 10 11 11 9
% (50) (55) (55) (45)
Female N 10 9 9 11
% (50) (45) (45) (55)
Table 2 BMI of the studied population.
Group 1 Group 2 P value Group 3 Group 4 P value
None obese control Obese control None obese asthmatics Obese asthmatics
(Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD)
BMI 22.9 ± 0.68 36.16 ± 3.15 t-Test <0.05 22.97 ± 1.13 34.9 ± 2.4 t-Test <0.05
BMI: body mass index (kg/m2).
Table 3 Level of control of asthmatic patients.
Group 3 (20
patient)
Group 4 (20
patient)
None obese
asthmatics
Obese
asthmatics
Day time symptoms N % N %
None 12 60 8 40
Once/w 4 20 4 20
Twice/w 4 20 8 40
Need for reliever
None 12 60 8 40
Once/w 4 20 4 20
Twice/w 4 20 8 40
Limitation of
activities
0 0
Night symptoms/
awakening
0 0 0 0
FEV1 92.6 ± 3.8 92.2 ± 3.6
PEF 81.8 ± 1.32 81.1 ± 1.37
Controlled 100% 100%
FEV1: forced expiratory volume in 1 second, PFE: peak expiratory
ﬂow.
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with P< 0.05.
Table 3 compares between group 3 and group 4 as regards
parameters of the level of asthma control. In none obese asth-
matic patients (group 3) 60% of patients experienced no day
time symptoms nor need for reliever while 20% was in need
for reliever once/week and the last 20% experienced day time
symptoms and the subsequent use of rescue medication. On the
other side, in obese asthmatic patients (group 4) 40% experi-
enced no daytime symptoms nor need for reliever while 20%
experienced day time symptoms once/week and was in need
for reliever medication once/week, the last 40% experienced
day time symptoms and subsequent use of rescue medication
twice/week. Both groups gave no history of limitation ofactivity or night symptoms/awakening with FEV1 and PEF
>80% in the last 4 weeks.
Table 4 demonstrates the mean value of FEV1 and PEF in
the studied population. There was a lower FEV1 and PEF of
obese groups than none obese groups, however there was no
signiﬁcant statistical difference as regards FEV1 and PEF
among none obese controls (96.95 ± 3.35, 82.8 ± 2.2) com-
pared to obese controls (94.7 ± 4.5, 82.2 ± 3.1) and none-
obese asthmatics (92.55 ± 3.8, 81.8 ± 1.32) compared to
obese asthmatics (92.2 ± 3.6, 81.1 ± 1.37), respectively.
In Table 5 there was a higher serum leptin level in obese
control (34.81 ± 2.32 pg/ml) compared to none obese control
(9.73 ± 0.78 pg/ml) with P< 0.05. Moreover, there was a
higher leptin serum level in obese asthmatic patients
(39.74 ± 3.26 pg/ml) compared to none obese asthmatic
patients (23.58 ± 1.99 pg/ml), with P< 0.01. There was a
lower adiponectin serum level in obese control (4.95 ± 1.32)
than non obese control (7.74 ± 3.13) and in obese asthmatic
patients (3.3 ± 1.4) than non obese asthmatic patients
(5.99 ± 1.5) with P< 0.01.
Table 6 and Fig. 1 demonstrate the positive correlation
between leptin serum level and BMI where (r= 0.87 and
P< 0.01).
On the other hand Table 7 and Fig. 2: demonstrates the
negative correlation between adiponectin serum level and
BMI where (r= 0.6 and P< 0.01).
Discussion
Whether activity restriction causes obesity or obesity by itself
causes the development of asthma has been questioned. The
possibility that asthma may lead to obesity is less controver-
sial, because of fear of exercise or inability to exercise regularly
[13]. Adipose tissue is an important source of cytokines and
contributes to the inﬂammatory state. Apart from general obe-
sity, visceral adipose tissue is the key factor in the formation of
low-grade chronic inﬂammation in obese individuals [14].
More than 50 different adipokines are secreted by adipocytes.
Adipokines are proteins that help regulate various body
Table 4 Spirometric pulmonary function of the studied population.
Group 1 Group 2 P value Group 3 Group 4 P value
None obese control Obese control None obese asthmatics Obese asthmatics
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
FEV1 96.95 ± 3.35 94.7 ± 4.5 t-Test >0.05 92.55 ± 3.8 92.2 ± 3.6 t-Test >0.05
PEF 82.8 ± 2.2 82.2 ± 3.1 >0.05 81.8 ± 1.32 81.1 ± 1.37 >0.05
FEV1: forced expiratory volume in 1 second, PFE: peak expiratory ﬂow.
Table 5 Comparison between leptin and adiponectin serum levels measured for the studied population.
Group 1 Group 2 P value Group 3 Group 4 P value
None obese control Obese control None obese asthmatics Obese asthmatics
(Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD)
Leptin 9.73 ± 0.78 34.81 ± 2.32 t-Test <0.01 23.58 ± 1.99 39.74 ± 3.26 t-Test <0.01
Adiponectin 7.74 ± 3.13 4.95 ± 1.32 <0.05 5.99 ± 1.5 3.3 ± 1.4 <0.01
Leptin serum level: pg/l, Adiponectin serum level: ng/l.
Table 6 Correlation between leptin serum level and BMI.
r P
Leptin serum level and BMI 0.87 <0.01
BMI: body mass index (kg/m2).
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Figure 1 Correlation between leptin serum level and BMI.
Table 7 Correlation between adiponectin serum level and
BMI.
r P
Adiponectin serum level and BMI 0.6 <0.01
BMI: body mass index (kg/m2).
r = -0.6
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Figure 2 Correlation between adiponectin serum level and BMI.
532 A. Salah et al.functions [15]. Leptin and adiponectin are two adipokines that
are being studied to determine their association with asthma
[16]. There has been intense interest in the potential role of adi-
pose tissue in the development of asthma in obesity. Adipose
tissue is an active endocrine organ elaborating cytokines and
hormones that regulate metabolism and immune responses.
In the lean state, adipose tissue typically secretes low levels
of proinﬂammatory cytokines (e.g., IL-6, IL-8, tumor necrosis
factor [TNFa]) and adipokines (e.g., leptin), and produces high
levels of the anti-inﬂammatory adipokine adiponectin. In the
obese state, adipose tissue hypertrophies and becomes inﬁl-
trated with proinﬂammatory macrophages. These activated
macrophages and hypertrophic adipocytes produce increased
proinﬂammatory cytokines and adipokines, and decreased adi-
ponectin; this ‘‘metabolic inﬂammation’’ is thought to produce
the systemic complications of obesity, such as type 2 diabetes,
steatohepatitis, and the metabolic syndrome [17]. Hence this
study was done to conﬁrm the interrelationship of leptin and
adiponectin serum levels with asthma and obesity.
All asthmatic patients included in this study were in a con-
trolled state according to GINA, 2012 [9] and this is in agree-
ment with Canoz et al. [11] and Scott et al. [12] who selected
Obesity/bronchial asthma interrelationship 533their asthmatic patients in a controlled state. Furthermore,
spirometric pulmonary function of the studied population
showed a lower FEV1 and PEF of obese groups than none
obese groups without signiﬁcant statistical difference; FEV1
and PEF between none obese control (group 1) compared to
obese controls (group 2) and none obese asthmatics (group
3) compared to obese asthmatics (group 4) and this is to con-
ﬁrm stability and group matching so the level of inﬂammatory
markers is independent to other modifying factors as one in
the study of Canoz et al. [11].
Our study showed a higher leptin serum level in obese
asthmatics compared to none obese asthmatics and in obese
control compared to none obese control and there was a highly
signiﬁcant statistical association between BMI and leptin
serum level with a positive correlation between BMI and leptin
serum level. This is in harmony with Scott et al. [12], Abdul
Wahab et al. [13], Nirav et al. [18], Bastard et al. [19], Sood
et al. [20] who found, especially in women, support for an
association of asthma with both serum leptin level and BMI
but after adjustment only the association with BMI remained
signiﬁcant, as of McLachian et al. [21] and Claude and
Cheryl [22]. However, the study of Jartti et al. [23] documented
that increase in BMI was also associated with incident asthma
during adulthood but serum levels of leptin, adiponectin or
any other obesity-related biomarker were not independently
associated with asthma. Adiponectin is one of the most abun-
dant gene products in adipose tissue. In contrast to many of
the other adipokines, the levels of which rise in obesity, plasma
adiponectin levels are decreased in obesity, and levels increase
following weight loss Kern et al. [24]. The study by Sood et al.,
[25] represented the ﬁrst step in understanding the role of adi-
ponectin in humans with asthma. Our study showed that
serum adiponectin levels were signiﬁcantly lower among obese
asthmatics compared to non obese asthmatics and negatively
correlated with BMI and this is in agreement with one study
each of children and adults showing a protective association
between serum adiponectin concentrations and risk for
asthma, but was independent of BMI which was done by
Sood et al. [26] and Nagel et al. [27]. However, Abdul
Wahab et al. [13] found serum adiponectin is lower in obese
asthmatics than none obese asthmatics in their studied pop-
ulation with a highly signiﬁcant statistical association between
BMI and adiponectin. As mentioned above, Jartti et al. [23]
did not ﬁnd an association between adiponectin and asthma.
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